Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP882945.RAsB26GvqatI-wMTFSHIB20IW6GcFa1qcB5Xfsq5jdroU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP882945.RAsB26GvqatI-wMTFSHIB20IW6GcFa1qcB5Xfsq5jdroU130_assertion type Assertion NP882945.RAsB26GvqatI-wMTFSHIB20IW6GcFa1qcB5Xfsq5jdroU130_head.
- NP882945.RAsB26GvqatI-wMTFSHIB20IW6GcFa1qcB5Xfsq5jdroU130_assertion description "[We estimated the cumulative incidence of first disease-free survival (DFS) events in the CNS versus other sites by competing risks analysis in patients with HER2-positive early breast cancer who had been randomly assigned to receive 1 year of trastuzumab or to observation in the HERA trial after a median follow-up of 4 years (IQR 3�5-4�8).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP882945.RAsB26GvqatI-wMTFSHIB20IW6GcFa1qcB5Xfsq5jdroU130_provenance.
- NP882945.RAsB26GvqatI-wMTFSHIB20IW6GcFa1qcB5Xfsq5jdroU130_assertion evidence source_evidence_literature NP882945.RAsB26GvqatI-wMTFSHIB20IW6GcFa1qcB5Xfsq5jdroU130_provenance.
- NP882945.RAsB26GvqatI-wMTFSHIB20IW6GcFa1qcB5Xfsq5jdroU130_assertion SIO_000772 23414588 NP882945.RAsB26GvqatI-wMTFSHIB20IW6GcFa1qcB5Xfsq5jdroU130_provenance.
- NP882945.RAsB26GvqatI-wMTFSHIB20IW6GcFa1qcB5Xfsq5jdroU130_assertion wasDerivedFrom befree-20150227 NP882945.RAsB26GvqatI-wMTFSHIB20IW6GcFa1qcB5Xfsq5jdroU130_provenance.
- NP882945.RAsB26GvqatI-wMTFSHIB20IW6GcFa1qcB5Xfsq5jdroU130_assertion wasGeneratedBy ECO_0000203 NP882945.RAsB26GvqatI-wMTFSHIB20IW6GcFa1qcB5Xfsq5jdroU130_provenance.